Non-Stimulant ADHD Options Beyond Qelbree and Strattera
The primary evidence-based non-stimulant alternatives to viloxazine (Qelbree) and atomoxetine (Strattera) are the alpha-2 adrenergic agonists: guanfacine extended-release and clonidine extended-release. 1
Alpha-2 Adrenergic Agonists: Your Next Options
Guanfacine Extended-Release (Intuniv)
- Dosing: Start at 1 mg once daily, adjust based on body weight (approximately 0.1 mg/kg as a rule of thumb), maximum 4 mg/day 1
- Onset: 2-4 weeks until therapeutic effects observed 1
- Administration: Evening dosing generally preferable due to somnolence/fatigue, though morning dosing is acceptable 1
- Effect size: Approximately 0.7 (medium range, smaller than stimulants at 1.0) 1, 2
Clonidine Extended-Release (Kapvay)
- Dosing: Start 0.1 mg at bedtime, can increase to twice-daily dosing, maximum 0.4 mg/day 1
- Available forms: Tablets and transdermal patch (0.1,0.2,0.3 mg) 1
- Onset: 2-4 weeks until therapeutic effects 1
- Note: Requires twice-daily dosing (unlike guanfacine's once-daily) 1
Key Advantages of Alpha-2 Agonists
Both medications offer specific benefits over atomoxetine and viloxazine:
- "Around-the-clock" symptom coverage without the limited duration seen with stimulants 1
- Non-controlled substances (no DEA scheduling concerns) 1
- First-line options for specific comorbidities: 1
- Substance use disorders (where stimulants are contraindicated)
- Tic disorders/Tourette's syndrome
- Disruptive behavior disorders
- Sleep disturbances (particularly beneficial here)
Common Pitfalls and Side Effects
Most frequent adverse effects (similar for both agents): 1
- Somnolence/sedation (most common—this is why evening dosing helps)
- Fatigue
- Irritability
- Hypotension/bradycardia
- Insomnia and nightmares
Critical monitoring requirements: 1
- Blood pressure and pulse at each visit
- Cardiovascular assessment before initiation
Important caveat: Atomoxetine has fewer and less pronounced adverse effects compared to clonidine and guanfacine 1, so if tolerability is the issue with Strattera, the alpha-2 agonists may present similar challenges.
Regarding Sunosi (Solriamfetol) for ADHD
Solriamfetol is NOT approved for ADHD and should not be used for this indication. 3, 4
However, solriamfetol is currently in Phase 3 clinical trials for ADHD treatment 3, 4. While it's FDA-approved for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, there is no established evidence for efficacy, safety, or appropriate dosing in ADHD. Using it off-label for ADHD would be premature and not evidence-based at this time.
The drug works as a dopamine and norepinephrine reuptake inhibitor, which theoretically could benefit ADHD, but clinical trial data must demonstrate actual benefit in ADHD populations before recommending its use 4.
Treatment Algorithm
When atomoxetine (Strattera) and viloxazine (Qelbree) are not options:
- First choice: Guanfacine ER (once-daily dosing, slightly better tolerability profile than clonidine) 1
- Second choice: Clonidine ER (if guanfacine fails or transdermal delivery preferred) 1
- Consider augmentation: Both alpha-2 agonists are FDA-approved as adjunctive therapy to stimulants in the US, which can enhance efficacy and reduce stimulant side effects 1
Special consideration: If the patient has comorbid sleep disturbances, tics, substance use disorder, or disruptive behavior, alpha-2 agonists may actually be preferable to atomoxetine/viloxazine as first-line non-stimulants 1.